Skip to main content
Fig. 2 | Allergy, Asthma & Clinical Immunology

Fig. 2

From: Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials

Fig. 2

Example to Illustrate the Reactive Dose. Step-up challenge dosing schedule for screening and exit DBPCFC for the PALISADE trial. Participants who were in the ARTEMIS (ARC010) trial had a maximum screening DBPCFC dose of 300 mg. Participants who tolerated doses of peanut protein had subsequently higher doses until a reactive dose was reached. The prior dose to the reactive dose was defined as the single highest tolerated dose, or maximum tolerated dose. DBPCFC double-blind, placebo-controlled food challenge

Back to article page